Intact Vascular Closes on Additional Series B Funding to Advance Development of the Tack Endovascular System® for Peripheral Artery Disease Treatment

New Enterprise Associates, Quaker Partners and H.I.G. BioHealth Partners exercise Series B investment option

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that current investors New Enterprise Associates, Quaker Partners and H.I.G. BioHealth Partners have exercised their right to invest additional capital as part of the Company’s Series B financing, bringing the total raised to $46 million. The Series B financing initially closed in May 2015. The funds will be used to advance the Company’s broad clinical development program, encompassing both above-the-knee (ATK) and below-the-knee (BTK) clinical trials, as well as a host of product development initiatives aimed at expanding the utility of the Tack Endovascular System for the treatment of peripheral artery disease.

Click here to read the full press release.


©2016 PACT All Rights Reserved